Soleno Therapeutics (SLNO) Acquisitions (2017)
Soleno Therapeutics (SLNO) posted quarterly Acquisitions of -$408.0 for Q4 2017, down 100.12% quarter-over-quarter from $350000.0 in Q3 2017.
Soleno Therapeutics (SLNO) Acquisitions (2017) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Acquisitions for 1 consecutive years, with -$408.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Acquisitions changed N/A year-over-year to -$408.0; the TTM figure through Dec 2017 stood at $349592.0 (changed N/A YoY), while the FY2017 annual figure was $572592.0, changed N/A from the prior year.
- Acquisitions fell to -$408.0 in Q4 2017 per SLNO's latest filing, from $350000.0 in the prior quarter.
- Across five years, Acquisitions topped out at $350000.0 in Q3 2017 and bottomed at -$408.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -408.00 |
| Sep 30, 2017 | 350,000.00 |